Share useful research with your peers
in · Share on LinkedIn ↗
BIOTECH ASSISTANT / FIELD NOTES

Direct-infusion method accelerates antibody peptide mapping in a peer-reviewed study

Academic source · Communications Chemistry

Source published: · Event / reporting date: 2026-11-06

Site published: 2026-11-07 · Updated: 2026-11-07

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

What the paper reports

A Communications Chemistry study reports RaPiD-mAb-MS, combining plate-based preparation with direct-infusion mass spectrometry for antibody peptide mapping. The original abstract describes analysis of 96 samples in about 1.5–2 hours, routinely exceeding 95% sequence coverage, across 28 antibodies and more than 2,000 samples. The reported comparisons cover several modifications and sequence variants; broader method suitability still requires evaluation.

Why this paper is included

Analysis: Higher-throughput mapping may shorten developability and formulation screens, while comparability, sensitivity, and quality-control validation remain application-specific requirements.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Edited by the Biotech Assistant content team and reviewed by an authorized publisher. Editorial standards and corrections

Biologics Characterization & CMC Analytics

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

Related updates

U.S. Food and Drug Administration

FDA finalizes lifecycle potency assurance guidance for cell and gene therapies

FDA announced final guidance on potency assurance for cellular and gene therapies on November 2. Its recommendations integrate manufacturing-process design, material and process controls, in-process testing, and lot-release potency assays. The agency emphasizes product-specific, risk-based strategies across development and commercialization; this is final guidance, not approval of any individual therapy.

mAbs

Setting expectations for current and future directions of native mass spectrometry in the biopharmaceutical industry

This industry perspective examines native mass spectrometry as a complement to established biopharmaceutical characterization methods. It discusses intact assemblies, binding, stoichiometry, and heterogeneity, while identifying throughput, sensitivity, automation, and access limitations. The authors emphasize integration with analytical workflows rather than universal replacement of existing methods.

BioAgilytix

BioAgilytix reports progress following its GMP analytical expansion

BioAgilytix reviewed its earlier analytical investment in Morrisville and Hamburg, describing infrastructure for GMP QC, characterization, bioassays, release, and stability programs. This is a May 2026 company update about previously expanded capabilities, not a newly announced November facility opening or independent quality certification.

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗
AI assistant ↗